CP and endothelial dysfunction: By inhibiting systemic chronic inflammation, SCFA significantly reduces lipid accumulation, foam cell formation, smooth muscle cell proliferation, endothelial dysfunction, and collagen degradation in the arterial wall, thereby inhibiting CP formation and disrupting more vulnerable plaques (de Vos et al., 2022).